Primary information |
---|
sequence ID | Seq_49 |
Peptide sequence | AAHLPAEFTPAVHASLDKFLASVSTVL |
CancerPDF_ID | CancerPDF_ID10646, CancerPDF_ID11087, CancerPDF_ID11100, |
PMID | 21805675,26482227,26482227 |
Protein Name | Hemoglobin subunit alpha,HBA_HUMAN,HBA_HUMAN |
UniprotKB Entry Name | HBA_HUMAN,HBA_HUMAN,HBA_HUMAN |
Fluid | Urine,Urine,Urine |
M/Z | 2792.4821,2790.7,2790.7 |
Charge | NA,NA,NA |
Mass (in Da) | NA,NA,NA |
fdr | NA,NA,NA |
Profiling Technique | MALDI-TOF,MALDI-TOF,MALDI-TOF |
Peptide Identification technique | MALDI-TOF-MS,LC-ESI-MS/MS,LC-ESI-MS/MS |
Quantification Technique | NA,NA,NA |
Labelled/Label Free | Label Free,Label Free,Label Free |
FDR | 1,FDR less than 5 %,FDR less than 5 % |
CancerPDF_ID | CancerPDF_ID10646, CancerPDF_ID11087, CancerPDF_ID11100, |
p-Value | NA,NA,less than 0.05 |
Software | NA,MASCOT,MASCOT |
Length | 27,NA,NA |
Cancer Type | Muscle-invasive bladder cancer,Clear cell renal carcinoma,Clear cell renal carcinoma |
Database | SwissProt Database,SwissProt Database,SwissProt Database |
Modification | NA,NA,NA |
Number of Patients | 751 bladder cancer and 127 control,"117 clear cell RCC patients (ccRCC) (72 men, 45 women)","117 clear cell RCC patients (ccRCC) (72 men, 45 women)" |
Regulation | Differentially expressed between cancer vs normal samples,"Differentially expression in control vs ccRCC cancer, Primary Tumor or grade",Upregulated in pT1b compared to pT1a patients |
Validation | Mann-Whitney tests and areas under receiver-operator characteristic,external cross validation not done,external cross validation not done |
Sensitivity | NA,NA,NA |
Specificity | NA,NA,NA |
Accuracy | NA,NA,NA |
Peptide Atlas | NA |
IEDB | 144183
|